Compare MNPR & MASS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MNPR | MASS |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 587.4M | 498.1M |
| IPO Year | 2019 | 2020 |
| Metric | MNPR | MASS |
|---|---|---|
| Price | $70.28 | $9.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 6 |
| Target Price | ★ $130.17 | $14.00 |
| AVG Volume (30 Days) | 127.0K | ★ 336.2K |
| Earning Date | 11-12-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 54.99 | ★ 125.47 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $56,197,000.00 |
| Revenue This Year | N/A | $23.13 |
| Revenue Next Year | N/A | $18.66 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $50.07 | $5.03 |
| 52 Week High | $124.82 | $13.35 |
| Indicator | MNPR | MASS |
|---|---|---|
| Relative Strength Index (RSI) | 42.77 | 39.10 |
| Support Level | $66.88 | $9.32 |
| Resistance Level | $75.33 | $11.16 |
| Average True Range (ATR) | 4.74 | 0.84 |
| MACD | 0.73 | -0.16 |
| Stochastic Oscillator | 51.81 | 19.52 |
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
908 Devices Inc develops a suite of purpose-built handheld devices for point-of-need chemical analysis. Leveraging mass spectrometry, optical spectroscopy, analytics and machine learning technologies, the company makes devices that are smaller and more accessible than conventional laboratory instruments. Its devices, including MX908, ThreatID, XplorIR and VipIR, are used to analyze unknown materials and provide actionable answers in health, safety and defense technology applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure and security threats. The company reimagines mass spectrometry technology by developing smaller, lower-cost and simpler-to-operate devices compared to conventional instruments, and generates maximum revenue from the United States.